onkologie2012.de

Hämoblastosen - Hodgkin-Lymphom - Weiterführende Informationen

Hodgkin-Lymphom

Leitlinien

www.kompetenznetz-lymphome.de; www.dgho.de; www.awmf-online.de

Studien

Studienprotokolle der Deutschen Hodgkin-Lymphom-Studiengruppe (GHSG: German Hodgkin Study Group): HD-16, HD-17, HD-18 (Primärtherapie), HD-R2 (Rezidivtherapie, geschlossen). Studienzentrale DHSG: Med.-Universitätsklinik I, Joseph-Stelzmann-Str. 9, 50924 Köln (Randomisation); Tel. (02 21)4 78–60 32, -35 55, -44 78, Fax -63 11, www.ghsg.org

Literatur

Borchmann et al: Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 367
Chen RW et al: Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lym-phoma (HL) J Clin Oncol 2011; 29: (suppl) #8031
Engert A et al: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495–502
Sieniawski M et al: Fertility in male patients with advanced Hodgkin Lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71–6